drugset / Trial / NCT01030536
Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary objectives of this study are to determine the maximum tolerated dose (MTD) or optimal biologic dose (OBD) and safety profile of CAT-8015 in participants with relapsed or refractory advanced B-cell NHL (diffuse large B-cell lymphoma \[DLBCL\], follicular lymphoma \[FL\], mantle cell lymphoma \[MCL\]) or CLL.
Timeline
- Start
- 2010-02-15
- Primary completion
- 2013-03-04
- Completion
- 2013-03-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Moxetumomab Pasudotox | Protein / enzyme biologic | 20 ug/kg | Intravenous |
| Subject | Moxetumomab Pasudotox | Protein / enzyme biologic | 30 ug/kg | Intravenous |
| Subject | Moxetumomab Pasudotox | Protein / enzyme biologic | 40 ug/kg | Intravenous |
| Subject | Moxetumomab Pasudotox | Protein / enzyme biologic | 50 ug/kg | Intravenous |
| Subject | Moxetumomab Pasudotox | Protein / enzyme biologic | 60 ug/kg | Intravenous |